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Abstract
Background: Interferon-γ-inducible protein 10 (IP-10) is a potent inhibitor of tumor angiogenesis.
It has been reported that the antiangiogenic therapy combined with chemotherapy has synergistic
effects.
Methods: To elucidate the mechanisms of IP-10 gene combined with a chemotherapy agent, we
intramuscularly injected pBLAST-IP-10 expression plasmid combined with gemcitabine into tumor-
bearing mice.
Results: The proliferation of endothelial cells was effectively inhibited by IP-10 combined with
gemcitabine in vitro. Treatment with pBLAST-IP-10 twice a week for 4 weeks combined with
gemcitabine 10 mg/kg (once a week) resulted in sustained high level of IP-10 protein in serum,
inhibition of tumor growth and prolongation of the survival of tumor-bearing mice. Compared with
administration of IP-10 plasmid or gemcitabine alone, the angiogenesis in tumors were apparently
inhibited, and the numbers of apoptotic cells and lymphocytes in tumor increased in the
combination therapy group.
Conclusion: Our data indicate that the gene therapy of antiangiogenesis by intramuscular delivery
of plasmid DNA encoding IP-10 combined with gemcitabine has synergistic effects on tomor by
inhibiting the proliferation of endothelail cells, inducing the apoptosis of tumor cells, and recruiting
lymphocytes to tumor in murine models. The present findings provided evidence of antitumor
effects of genetherapy combined with chemotherapy.
Background
Angiogenesis, the formation of new blood vessels, is
important not only for normal physiological processes,
but also for the development of pathologic conditions
such as cancer, rheumatoid and inflammation. Presently,
accumulated evidences indicate that the growth and
metastasis of solid tumors is dependent on angiogenesis.
Therefore, targeting tumor vasculature has been a popular
strategy of therapeutics [1,2]. But anti-angiogenesis alone
is not sufficient due to the angiogenesis-independent
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phase of tumor growth. It has been reported that cytotoxic
agents can impair neovasculature directly or indirectly [3].
Further, proliferative endothelial cells in new vessels are
sensitive to cytotoxic agents [4]. Combination therapy,
consisting of low-dose chemotherapy and antiangiogen-
esis, may produce improved efficacy and reduced toxicity
due to the synergistic effect on tumors [4,5].
Interferon-γ-inducible protein 10 (IP-10), a member of
the α chemokine family, is secreted by activated T cells,
fibroblast and endothelial cells [6]. It attracts activated,
but not resting, T lymphocytes and NK cells [7-9] via stim-
ulating CXCR3 chemokine receptor [7]. Tumor cell lines
stably transfected with the IP-10 gene were rejected by
immune-system [10]. Intratumoral injection of IP-10
gene facilitated regression of established mice tumors
[11]. IP-10 is also a potent inhibitor of angiogenesis
[10,12]. Thus, we hypothesize that IP-10, which is
involved in immune (T and NK cells) and antiangiogenic
responses, is a good candidate for treatment of malignant
tumors.
Gemcitabine (GEM), a deoxycytidine analog, is currently
used as a therapeutic agent against several solid tumors,
such as non-small cell lung cancer (NSCLC), pancreatic
cancer and bladder cancer [13]. In local advanced or met-
astatic NSCLC, gemcitabine has been used as the first-line
therapeutic. However, the efficacy of gemcitabine is unsat-
isfactory with a response rate of only about 36%, and time
of tumor progression is 4 to 5 months. [14] Therefore we
sought to develop therapeutic agents that would increase
the anti-tumor efficacy of gemcitabine. IP-10 may
enhance the effects of gemcitabine in combination ther-
apy via angiogenic-independent mechanisms. In 2005, a
synergistic effect of their combination on solid tumors
was found by our study group [15]. In this study, we try to
elucidate the mechanism of combination of IP-10 with
gemcitabine.
Materials and methods
Preparation of IP-10 plasmid
pBLAST-IP-10 plasmid (purchased from Invivogen, San
Diego, CA, USA) was transformed into E. coli JM109, and
cultured at 37°C for plasmid isolation by endotoxin-free
plasmid maxiprep kit (Roche, Germany). The concentra-
tion of pBLAST-IP-10 plasmid was determined by ultravi-
olet spectrophotometer.
Transfection of COS cells with pBLAST-IP-10
COS cells were plated in six-well plates at 2 × 105 cells/
well in DMEM containing 10% FBS at 37°C overnight.
Cells at 60–80% confluence were transfected with 2 μg of
plasmid and 6 μl lipofectamine (Invitrogen) in serum-free
DMEM following the manufacture's instructions. After
addition of the lipofectamine-DNA complex, the cells
were incubated at 37°C for 12 h. Then the complex was
replaced with normal growth medium and the cells were
incubated at 37°C for an additional 60 h before collection
of the conditioned medium.
Western blot analysis
IP-10 protein produced by pBLAST transfected COS cell
was analyzed by Western blot. Briefly, ten microliters of
the conditioned media were mixed with 2 × sodium
dodecyl sulfate sample buffer and were separated on a
12% SDS-PAGE gel. Gels were electroblotted with Sarto-
blot on to a poly (vinylidene difluoride) membrane. The
membrane blots were blocked in 5% non-fat dry milk,
washed, and probed with rabbit-anti-murine IP-10 anti-
body (Pepro Tech House, USA) at 0.2 μg/ml at 4°C over-
night. Blots were then washed and incubated with a
biotinylated secondary antibody (biotinylated goat anti-
rabbit IgG), followed by transfer to Vectastain ABC (Vec-
tor Laboratories, Burlingame, CA, USA) [16].
Effect of IP-10 and gemcitabine on endothelial cell in vitro
Biological activity of IP-10 and gemcitabine on HUVEC
was determined using conditioned medium from trans-
fected cells in endothelial cell proliferation assay. Briefly,
3 × 103 endothelial cells (human umbilical vein endothe-
lial cells, HUVECs; and a cell line of mouse endothelial
cells, SVECs) and non-endothelial cells (NIH/3T3 fibrob-
last) were plated on to 96-well culture plates in triplicate,
and incubated (37°C, 5% CO2) for 24 h in 100 μl
medium containing bFGF. Then the medium was replaced
with 40 μl of normal saline or IP-10-containing superna-
tant from transfected COS cells or control cells. Gemcitab-
ine was added at final concentration from 20 μM to 100
μM. After incubation for 20 min, 60 μl of medium was
added. After another 72 h of incubation, the cell number
was determined by trypan blue dye exclusion test, and the
percent growth inhibition of HUVECs and NIH/3T3
fibroblast was calculated by the following formula: inhi-
bition % = [(N-NT)/(N-N0)] × 100, where N is the number
of cells in the untreated control cultures after n days, N0 is
the cell number on day 0, and NT is the number of cells in
the treatment group after n days [16,17].
Tumor models
Tumor cell injections were carried out using freshly pre-
pared cell suspensions at a concentration of 1 × 107 cells/
ml in PBS. C57BL/6 and BALB/c female mice about 20 g
body weight were inoculated subcutaneously (s. c.) in the
right flank with 1 × 106 LL/2c Lewis lung cancer cells and
H22 hepatocarcinoma cells, respectively, as previously
described [18].
Tumor growth inhibition study
After tumor model had been established, the mice were
weighed, coded and randomly divided into differentJournal of Experimental & Clinical Cancer Research 2008, 27:63 http://www.jeccr.com/content/27/1/63
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groups with 10 mice per group. Mice were injected with
different doses of IP-10 plasmid (100 μg, 50 μg, 12.5 μg)
into both quadriceps twice weekly for 4 weeks (empty
plasmid and saline as controls). At the conclusion of the
treatment, tumor volume was measured. The optimal
dose of IP-10 plasmid was selected for use in combination
therapy with gemcitabine. Gemcitabine (Lilly Pharmaceu-
tical Co. U.S.A) was administered alone or in combina-
tion with IP-10 plasmid by i.p. injections (10 mg/kg, 1/12
of the maximal tolerance dose) on days 14 and 21 after
initial of IP-10 plasmid injection. Additional control ani-
mals were injected with normal saline 100 μl. The doses
of gemcitabine selected were determined after optimum
dose experiment (data not shown). Survival times and
tumor volumes were observed.
ELISA determination of IP-10 expression
The levels of IP-10 in serum after intramuscular adminis-
tration of IP-10 plasmid were assayed by ELISA. In brief,
96-well microtiter plates (Falcon) were coated with rab-
bit-anti-IP-10 antibody in 100 mM coating buffer (car-
bonate-bicarbonate, pH 9.6) at 4°C overnight and
blocked with 150 μl/well of 1% bovine serum albumin in
phosphate-buffered saline (PBS) at 37°C for 1 h. Sera
diluted 1/5 (100 μl/well) was added and incubated for 2
h at 37°C. Horseradish peroxidase-conjugated goat anti-
rabbit IgG (Sigma, St Louis, MO, USA) diluted 1/5000 in
PBS-Tween-BSA buffer was added (100 μl/well) and incu-
bated for 1 h at 37°C. After washing four times with PBST,
ABTS (100 μl/well) (Sigma) was added for 30 min, and
absorbance was measured at 450 nm with an ELISA reader
(BioRad, Hercules, CA, USA). A dilution series of recom-
binant IP-10 was used as a standard. Assays were done in
triplicate.
Alginate encapsulation assay
Alginate-encapsulated tumor cell assays were performed
as described previously [19]. Meth A cells were directly
dispersed in a 1.5% solution of sodium alginate after cen-
trifugation and added dropwise into a swirling solution of
250 mM calcium chloride at 37°C. Each alginate bead
contained approximately 1 × 105 tumor cells. Mice were
then anesthetized, 4 beads were implanted subcutane-
ously into an incision made on the dorsal side, and then
the incisions were sutured. Mice were randomized into
four groups (10 mice per group) and treated with normal
saline, IP-10 plasmid alone, gemcitabine alone or IP-10
plasmid combined with gemcitabine. Treatment was initi-
ated on days 2 following beads implantation with injec-
tion of IP-10 plasmid i.m. (100 μg/day for each mouse,
twice weekly over a 2-week period) in both quadriceps, or
gemcitabine i. p. twice (10 mg/kg) on days 5 and 11, or
both agents together. Normal saline (100 μl) was admin-
istered as control. Twelve days after implanting alginate
beads, the mice were injected intravenously with 100 μl of
a 100 mg/kg fluorescein isothiocyanate (FITC)-dextran
solution (Sigma). Alginate beads were surgically removed,
and FITC-dextran was quantified against a standard curve
of FITC-dextran.
Histological analysis
To assess the formation of blood vessel of tumor tissues,
immunohistochemistry was done as described [20]. Fro-
zen sections were fixed in acetone and incubated with a
monoclonal rabbit anti-mouse CD31 at a 1:200 dilution
(Pharmingen, San Diego, CA, USA) at 4°C overnight.
After sections were washed with PBS, biotinylated rabbit
anti-mouse secondary antibody was added at a 1:100
dilution (Dako, Carpinteria, CA, USA). The sections were
then stained with labeled streptavidin biotin reagents
(Dako LSAB kit, peroxidase). Vessel density was deter-
mined by counting the number of microvessels per high-
power field in the sections [17,21].
Apoptotic cells were identified by TUNEL assay (an in situ
apoptotic cell detection kit based on the enzymatic addi-
tion of deoxyadenine-nucleotide to the nicked DNA by
terminal deoxynucleotidyl transferase) following the pro-
tocol supplied by manufacture (Boehringer Mannheim).
Tumor tissues from each group were fixed in 10% neutral
buffered formalin solution, embedded in paraffin. Sec-
tions 3–5 μm thick were stained with H&E according to
standard procedure [22]. Pathologists were blinded for
quantitation of infiltrating lymphocytes as previously
described [23].
To identify possible side effects resulting from IP-10 plas-
mid and gemcitabine, sections of paraffin-embedded tis-
sues, including liver, kidney, lung, heart and spleen, were
stained by H&E.
Statistic analysis
Data is expressed as mean ± SD. Statistical significance
was determined by Student's t test. Kaplan-Meier curves
were established for the survival time of mice from each
group and survival was compared by means of the log-
rank test. Differences between variables or ranks were con-
sidered significant when yielding a P < 0.05.
Results
Expression of biologically active IP-10 in vitro
Large-scale endotoxin-free expression pBLAST-IP-10 plas-
mid was purified and transfected into COS cells. Western
blot analysis was used to determine expression of IP-10
protein (Fig. 1A). Conditioned medium was obtained
from COS cells transfected with empty plasmid (lane a),
non-transfected cells (lane b) and cells transfected with
pBLAST-IP-10 (lane c). IP-10 immunoreactivity at ~10 KDJournal of Experimental & Clinical Cancer Research 2008, 27:63 http://www.jeccr.com/content/27/1/63
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Expression of IP-10 in vitro after transfection into COS cells Figure 1
Expression of IP-10 in vitro after transfection into COS cells. IP-10 expression in vitro and inhibition proliferation of 
endothelial cells by IP-10 combined with gemcitabine. A. Western blotting analysis of secreted IP-10 by COS cells. Conditioned 
media was obtained from COS cells transfected with empty plasmid or pBLAST-IP-10, or from non-transfected cells. The pro-
tein mass molecular markers are indicated on the right. B. Inhibition of endothelial cell proliferation by IP-10 combined with 
gemcitabine. Exponentially growing HUVEC, SVEC, NIH/3T3 were exposed to the conditioned medium from COS cells trans-
fected with pBLAST-IP-10 for 72 h, or exposed to normal saline and gemcitabine. The rate of cell proliferation inhibition was 
calculated. Combination treatment significantly inhibited the proliferation of endothelial cells compared with gemcitabine alone, 
or IP-10 alone or other controls. *, P < 0.05; and **, P < 0.01.Journal of Experimental & Clinical Cancer Research 2008, 27:63 http://www.jeccr.com/content/27/1/63
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was only identified in the lane from the transfected cul-
tures.
Inhibition of endothelial cell proliferation by IP-10 
combined with gemcitabine
The biological activity of secreted IP-10 was tested against
human umbilical vein endothelial cells (HUVECs primary
cells) and a cell line of mouse endothelial cells (SVEC). As
a control, the conditioned medium was also tested against
non-endothelial cells (mouse NIH/3T3 fibroblast cells).
Compared with the medium from the COS cells trans-
fected with control vector or nontransfected cells, condi-
tioned medium from IP-10-transfected COS cells
inhibited HUVEC and SVEC endothelial cell growth.
However, it had no effect on proliferation of non-
endothelial cells (Fig. 1B). The proliferation of endothe-
lial cells was inhibited by IP-10 combined with gemcitab-
ine, compared with normal saline, IP-10 alone or
gemcitabine alone.
Serum level of IP-10 after intramuscular administration of 
plasmid pBLAST-IP-10
Selected doses (12.5 μg, 50 μg, 100 μg and 200 μg) of
pBLAST-IP-10 plasmid and empty plasmid were adminis-
tered by intramuscular injection to mice twice a week for
4-week. Serum was collected on days 0, 2, 7, 14, 21, 28
and 35, and IP-10 levels were determined by ELISA. Treat-
ment with pBLAST-IP-10 resulted in the elevated IP-10
serum levels compared with empty plasmid or normal
saline (Fig. 2). In addition, similar levels of IP-10 protein
were achieved by administration of 100 μg and 200 μg
plasmid, and they were higher than those by administra-
tion of 12.5 μg and 50 μg plasmid, empty plasmid and
normal saline.
The antitumor effects of IP-10 plasmid combined with 
gemcitabine
Inhibition of tumor growth by IP-10 plasmid injection
was found to be dose-dependent (Fig. 3). The mice were
injected intramuscularly with IP-10 plasmid (12.5 μg, 50
μg and 100 μg), empty plasmid or normal saline. Injec-
tion with 100 μg of IP-10 plasmid twice weekly for 4
weeks induced reduced tumor volume compared with the
controls.
Treatment of the mice with combination therapy was ini-
tiated when tumors were palpable on 7 days following
injection of H22 hepatocarcinoma or LL/2c Lewis lung
cancer cells. In both tumor models, the combination ther-
apy was consisted of intramuscular injection of pBLAST-
IP-10 plasmid (100 μg) and intraperitoneal injection of
gemcitabine (10 mg/kg). IP-10 plasmid was administered
twice weekly for 4 weeks, and once-weekly administration
of gemcitabine initiated a week following the first IP-10
injection. The combination therapy of IP-10 plasmid and
gemcitabine resulted in inhibition of tumor growth (Fig.
4A–B). On the day 32, the tumor volume inhibition rates
Increased serum levels of IP-10 after intramuscular adminis- tration of IP-10 plasmid Figure 2
Increased serum levels of IP-10 after intramuscular 
administration of IP-10 plasmid. Empty plasmid (control, 
100 μg, open circles) or selected doses of IP-10 plasmid (12.5 
μg, solid circles, 50 μg, open rhombus, 100 μg, solid rhom-
bus, 200 μg, open triangles) were administered by intramus-
cular injection. Mice were treated twice weekly over a 4-
week period. Serum was collected on days 0, 2, 7, 14, 21, 28 
and 35. IP-10 protein was determined by ELISA.
Effects of DNA dose on tumor growth by intramuscular  administration of pBLAST-IP-10 Figure 3
Effects of DNA dose on tumor growth by intramus-
cular administration of pBLAST-IP-10. Empty plasmid 
(control, 100 μg, open circles), normal saline (control, 100 
μg, solid triangles) and selected doses of IP-10 plasmid (12.5 
μg, solid circles, 50 μg, open rhombus, 100 μg, solid rhom-
bus) were administered by intramuscular injection. Mice 
bearing Lewis lung cancer were injected twice weekly for 4 
week.Journal of Experimental & Clinical Cancer Research 2008, 27:63 http://www.jeccr.com/content/27/1/63
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in combined therapy group were 85% and 81.2% in H22
and LL2 bearing mice respectively, which were higher
than that in IP-10 therapy group (61.5% and 53% in H22
and LL2 respectively, both P < 0.01). Further, the pro-
longed survival of tumor-bearing mice was observed in
the combination group, although both kinds of tumor-
bearing mice died from progressive tumors. The average
life spans of normal saline treated mice bearing with H22
and LL2 tumor were 30.7 days and 31 days respectively.
They were increased to 37.9 days (H22) and 38.2 days
(LL2) in gemcitabine group, and to 58.2 days (H22) and
57.6 days (LL2) in IP-10 group. In contrast, the combined
treatment resulted in significant increases to 69 days in
H22 bearing mice, and 70 days in LL2 bearing mice (P <
0.05, by log-rank test) (Figures 4C and 4D).
Antitumor efficacy of IP-10 plasmid combined with gemcitabine in two murine models Figure 4
Antitumor efficacy of IP-10 plasmid combined with gemcitabine in two murine models. Mice (ten mice per group, 
including normal saline, solid triangles, gemcitabine alone, open triangles, IP-10 plasmid alone, solid circles, IP-10 plasmid com-
bined with gemcitabine, open circles) were treated with injection of IP-10 plasmid 100 μg (i. m.) twice weekly for 4 weeks and/
or administration of gemcitabine i.p. cycled twice (10 mg/kg, on the days 14 and 21 after initial of IP-10 plasmid administration). 
Normal saline 0.1 ml was injected as control. The treatment started at day 7 after 1 × 106 hepatocarcinoma cells (A, C) or 
Lewis lung cancer cells (B, D) were injected subcutaneously into mice. Combined treatment with IP-10 plasmid and gemcitab-
ine resulted in significant inhibition of tumor growth and longer life span versus other three controls.Journal of Experimental & Clinical Cancer Research 2008, 27:63 http://www.jeccr.com/content/27/1/63
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Gross measures of toxicity, such as alterations in weight
loss, fur ruffling, life span, behavior and feeding, were not
observed in any of the treatment groups. Further, micro-
scopic examination of hematoxylin and eosin (H&E)
stained tissue sections of heart, liver, spleen, lung, and
kidney did not provide evidence of pathologic changes in
any of the treatment groups.
Inhibition of angiogenesis
The effects of IP-10 plasmid and gemcitabine on tumor
vasculature were determined by immunohistochemical
staining for CD31 and estimation of angiogenesis via
microvessel counts. The combination of IP-10 plasmid
and gemcitabine resulted in the inhibition of the angio-
genesis in tumors (Fig. 5D) compared to controls (Fig.
5A–C). The numbers of vessels in tumor sections from
mice in combined treatment group (8.51 ± 1.09/HPF and
9.13 ± 2.25/HPF in LL/2 and H22 respectively) were sig-
nificantly less than that in IP-10 alone group (17.37 ±
2.75/HPF and 17.81 ± 3.85/HPF in LL/2 and H22 respec-
tively, both P < 0.05) and other two control groups (P <
0.01, Fig. 5E).
The inhibition of angiogenesis in the combination ther-
apy was confirmed by the alginate encapsulation assay.
Angiogenesis was quantitated by measuring the uptake of
FITC-dextran into implanted alginate beads. The vascular-
ization of alginate beads was significantly reduced with
74% decreased FITC-dextran uptake in the combination
therapy group (Fig. 6D) compared with normal saline
group (Fig. 6A), while 57% decreased FITC-dextran
uptake in IP-10 group (P < 0.05, Fig. 6C).
Increased apoptosis in combination therapy group
To investigate the effect of combination of IP-10 plasmid
DNA with gemcitabine on apoptosis of tumor cells, for-
maldehyde-fixed and paraffin embedded sections from
tumor tissues were analyzed by TUNEL assay. Apoptotic
cells with condensed chromatin dispersed throughout the
sections. Treatment with IP-10 plasmid or gemcitabine
alone slightly affected the apoptotic rate of tumor cells
compared with normal saline (P < 0.05), whereas com-
bined treatment induced increased number of apoptotic
cells than other three controls (all P < 0.01, Fig. 7).
Histological analysis
Combination treatment resulted in obvious lymphocyte
infiltration in tumor tissues, compared with treatment of
IP-10 plasmid, or gemcitabine alone, or normal saline.
Representative sections of four treated groups from H22
neoplasm tissue were depicted (Fig. 8A–D). Quantitation
of tumor-infiltrating lymphocytes revealed apparent dif-
ferences in combination treated group relative to other
three groups in both H22 and LL/2 neoplasm tissues (all
P < 0.01, Fig. 8E).
Except for the mild degeneration of parenchyma cells, no
obvious pathologic changes was found in H&E stained
sections of heart, liver, spleen, lung and kidney.
Discussion
Interferon-γ-inducible protein 10 (IP-10) is a potent
inhibitor of angiogenesis, and may be a downstream
mediator in interferon-induced antiangiogenesis. IP-10
plays an important role in antitumor activity via at least
two possible mechanisms: 1) inhibition of tumor angio-
genesis and 2) attraction of lymphocytes in the tumor tis-
sue. It has been shown that intratumor administration of
IP-10 plasmid induced tumor regression and inhibited
tumor metastasis. IP-10 has also been investigated in
combination with various cytokines against tumors [24].
In 2005, our study group developed a novel combination
therapy consisting of IP-10 plasmid and a chemothera-
peutic agent, gemcitabine (2', 2'-difluorodeoxycytidine),
for the treatment of solid tumors [15].
Gemcitabine is a nucleoside analogue of cytidine, and its
metabolites are embedded into DNA strand with the sub-
sequent addition of one base, thus halting DNA synthesis.
Cellular DNA repair systems are unable to correct for this
process, leaving the cells vulnerable to apoptosis. Cur-
rently, gemcitabine is therapeutically used against a wide
range of solid tumors as a single agent and in combina-
tion with other drugs, such as cisplatin [7,25]. In the
present study, we found that combination IP-10 with
gemcitabine resulted in prolonged survival and shrink
tumors in a murine model, indicating its antitumor effi-
cacy.
Chemotherapy agents have been reported to inhibit
directly and indirectly the growth of vascular endothelial
cells [3]. Gemcitabine inhibited the growth of HUVECs
with an IC50 of 0.08 mM [26]. In our study, the prolifer-
ation of vascular endothelial cells was significantly inhib-
ited  in vitro by combination IP-10 with gemcitabine
compared with IP-10 alone or gemcitabine alone, suggest-
ing the antitumor mechanism of the combination therapy
may be, at least in part, due to inhibition of the prolifera-
tion of vascular endothelial cells.
Gemcitabine is effective in inducing apoptosis of a variety
of cancer cells, including non-small cell lung cancer, pan-
creatic, gastric and hepatic cancer [27]. IP-10 has been
shown to inhibit tumor angiogenesis. We hypothesized
that gemcitabine and IP-10 would act synergistically in
their anti-angiogenesis and inducing apoptosis. In this
study, decreased angiogenesis and increased apoptosis
were observed when IP-10 was administered in combina-
tion with gemcitabine. The growth and proliferation of
endothelial cells are stimulated, in part, by the vascular
endothelial growth factor secreted spontaneously byJournal of Experimental & Clinical Cancer Research 2008, 27:63 http://www.jeccr.com/content/27/1/63
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Anti-angiogenesis assay by immunohistochemical analysis with CD31 Figure 5
Anti-angiogenesis assay by immunohistochemical analysis with CD31. Inhibition of angiogenesis within tumor from 
IP-10 plasmid combined with gemcitabine therapy mice was estimated by immunohistochemical analysis. Sections of frozen LL/
2 tumor tissues obtained from mice treated with normal saline (A), gemcitabine (B), IP-10 plasmid (C) and IP-10 plasmid com-
bined with gemcitabine (D). Vessel density was determined by counting the number of microvessels per high-power field (E) in 
tumor sections stained with an antibody reactive to CD31 (brown). Original magnification, ×200 (A-D). *, P < 0.05, versus nor-
mal saline group; **, P < 0.01 versus gemcitabine and normal saline group; and #, P < 0.05, versus IP-10 group.Journal of Experimental & Clinical Cancer Research 2008, 27:63 http://www.jeccr.com/content/27/1/63
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Inhibition of angiogenesis assay by alginate beads in vivo Figure 6
Inhibition of angiogenesis assay by alginate beads in vivo. Beads containing 1 × 105 Meth A cells were implanted subcu-
taneously into BALB/c mice on day 7 after the treatment with IP-10 plasmid or gemcitabine. Twelve days later, beads were sur-
gically removed, and FITC-dextran was quantified. FITC-dextran uptake (E) and representative photograph of alginate beads of 
normal saline (A), gemcitabine (B), IP-10 plasmid (C) and IP-10 plamsid combined with gemcitabine (D). The images of alginate 
implants and FITC-dextran uptake showed the reduction of vascularization in combination treatment and IP-10 plasmid treated 
alone group compared with normal saline controls. *, P < 0.01 versus normal saline and gemcitabine group; and #, P < 0.01 ver-
sus IP-10 group.Journal of Experimental & Clinical Cancer Research 2008, 27:63 http://www.jeccr.com/content/27/1/63
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Increased apoptosis in tumors after being treated with IP-10 plasmid Figure 7
Increased apoptosis in tumors after being treated with IP-10 plasmid. Representative sections from LL/2 tumors 
were presented in normal saline (A), gemcitabine (B), IP-10 plasmid (C) and IP-10 plasmid combined with gemcitabine (D) 
groups. Bars represented apoptotic index of tumor tissues from LL/2 (open bars) and H22 (solid bars) (E). IP-10 plasmid com-
bined with gemcitabine induced increased apoptosis compared with saline control (**, P < 0.01), also IP-10 plasmid alone or 
gemcitabine alone versus normal saline (*, P < 0.05).Journal of Experimental & Clinical Cancer Research 2008, 27:63 http://www.jeccr.com/content/27/1/63
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Increased lymphocytes infiltration induced by IP-10 plasmid combined with GEM (× 200) Figure 8
Increased lymphocytes infiltration induced by IP-10 plasmid combined with GEM (× 200). Representative sections 
of four treated groups from H22 neoplasm tissue were photomicrographed at ×200 magnification (A-D). A few lymphocytes 
infiltrated in tumor tissues of normal saline group (A). Lymphocyte infiltration increased by administration of GEM (B) or IP-10 
plasmid DNA (C). A further increase of lymphocyte infiltration was induced by IP-10 DNA combined with GEM (D) in H22 and 
LL/2 tumor tissues (E). *, P < 0.01 versus normal saline; and **, P < 0.01 versus GEM alone and IP-10 alone.Journal of Experimental & Clinical Cancer Research 2008, 27:63 http://www.jeccr.com/content/27/1/63
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tumor cells [28]. Increased apoptosis of tumor cells may
result in reduced secretion of vascular endothelial growth
factor from tumor cells, which may induce decreased ang-
iogenesis. Intramuscular injection of IP-10 plasmid
resulted in constitutively high expression levels in vivo
(had been confirmed in our experiment). Vascular repair
occurs during interphase necessitates the continuous
administration of chemotherapy [29]. The possible inhi-
bition of blood vessel repair induced by IP-10 explains the
enhanced antitumor efficacy of the combination therapy
in the current report.
It has been reported that the antitumor effect of IP-10 is
dependent on T cells. Further, IP-10 has been shown to
induce protective antitumor immunity via specific CD8+ T
cells [30]. IP-10 is also a chemoattractant for monocyte
and T lymphocyte. Histologic analyses have demonstrated
that lymphocytes and neutrophils infiltrated into the
tumor region [8,31]. In our study, the combination treat-
ment resulted in obvious lymphocyte infiltration in
tumor tissues, compared to the IP-10 plasmid, GEM or
normal saline treatments. The results suggest that lym-
phocyte infiltration may also account for the enhanced
antitumor efficacy of combination treatment.
Chemotherapy agents often result in cytotoxic responses
and are fraught with various side effects. Many of the pro-
nounced side effects in conventional chemotherapy can
be avoided with the application of low dose gemcitabine.
In the present study, we selected low dose gemcitabine
(10 mg/kg, 1/12 of maximum dose) in the combination
therapy [13]. Based upon the resulting serum levels of IP-
10, the 100 μg dose of plasmid per injection was identi-
fied as the optimal dose. In this study, no obvious side
effects were observed in the combination treatment
group, suggesting IP-10 and gemcitabine may be safely
applied in combination protocols [32].
In conclusion, our study indicates that combination ther-
apy with IP-10 plasmid and gemcitabine is a well-toler-
ated protocol with enhanced antitumor activity. This
antitumor activity may be due, in part, to inhibition of
angiogenesis via their effects on endothelial cells and
attraction of lymphocytes into tumor tissues. These find-
ings are important for further exploration of potential
clinic application of the combined approach.
Conclusion
In this study, we tested the mechanisms of a novel combi-
nation therapy consisting of IP-10 plasmid DNA and gem-
citabine for the treatment of solid tumors. Gene therapy
of anti-angiogenesis by intramuscular delivery of plasmid
DNA encoding IP-10 combined with gemcitabine was
effective in inhibition of angiogenesis by suppressing the
proliferation of endothelial cells, and induction of lym-
phocytes infiltration in tumor tissues and the apoptosis of
tumor cells in murine models. The present findings also
provided evidence of antitumor effects of gene therapy
combined with chemotherapy.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
KM and LW participated in its design, discussed the
results, drafted the manuscript and carried out cell culture,
western blot, ELISA and immunohistochemical and histo-
logical analysis. ZZ helped to establish animal tumor
models. JY carried out experiments, data collection and
statistical analysis, and helped to write the manuscript.
YW and LT conceived of the study and participated in its
design. All authors read and approved the final manu-
script.
Acknowledgements
This study was supported by grants from National Basic Research Program 
of China (2001CB510001, 2004CB518800), the projects of National Natu-
ral Science Foundation of China, and National 863 Program. We thank 
Department of Oncology, Sichuan Cancer Hospital for assistance in writing 
the manuscript.
References
1. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometas-
tases: balanced proliferation and apoptosis in the presence of
angiogenesis suppression.  Nat Med 1995, 1:149-153.
2. Gasparini G: The rationale and future potential of angiogen-
esis inhibitors in neoplasia.  Drugs 1999, 58:17-38.
3. Kerbel RS: Tumor angiogenesis: past, present and the near
future.  Carcinogenesis 2000, 21:505-515.
4. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P,
Kerbel RS: Continuous low-dose therapy with vinblastine and
VEGF receptor-2 antibody induces sustained tumor regres-
sion without overt toxicity.  J Clin Invest 2000, 105:R15-24.
5. Sweeney CJ, Miller KD, Sissons SE, Nozaki S, Heilman DK, Shen J,
Sledge GW Jr: The antiangiogenic property of docetaxel is syn-
ergistic with a recombinant humanized monoclonal anti-
body against vascular endothelial growth factor or 2-
methoxyestradiol but antagonized by endothelial growth
factors.  Cancer Research 2001, 61:3369-3372.
6. Farber JM: Mig and IP-10: CXC chemokines that target lym-
phocytes.  J Leukoc Biol 1997, 61(3):246-257.
7. Loetscher M, Loetscher P, Brass N, Meese E, Moser B: Lym-
phocyte-specific chemokine receptor CXCR 3: regulation,
chemokine binding and gene localization.  Eur J Immunol 1998,
28:3696-3705.
8. Taub DD, Lloyd AR, Conlon K, Wang JM, Ortaldo JR, Harada A, Mat-
sushima K, Kelvin DJ, Oppenheim JJ: Recombinant human inter-
feron-inducible protein 10 is a chemoattractant for human
monocytes and T lymphocytes and promotes T cell adhesion
to endothelial cells.  J Exp Med 1993, 177:1809-1814.
9. Loetscher P, Seitz M, Clark-Lewis I, Baggiolini M, Moser B: Activa-
tion of NK cells by CC chemokines: chemotaxis, Ca21 mobi-
lization, and enzyme release.  J Immunol 1996, 156:322-327.
10. Sgadari C, Angiolillo AL, Cherney BW, Pike SE, Farber JM, Koniaris
LG, Vanguri P, Burd PR, Sheikh N, Gupta G, Teruya-Feldstein J,
Tosato G: Interferon-inducible protein-10 identified as a
mediator of tumor necrosis in vivo.  Proc Natl Acad Sci USA 1996,
93:13791-13796.
11. Liu Y, Huang H, Saxena A, Xiang J: Intratumoral coinjection of
two adenoviral vectors expressing functional interleukin-18
and inducible protein-10, respectively, synergizes to facili-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Experimental & Clinical Cancer Research 2008, 27:63 http://www.jeccr.com/content/27/1/63
Page 13 of 13
(page number not for citation purposes)
tate regression of established tumors.  Cancer gene ther 2002,
9:533-542.
12. Angiolillo AL, Sgadari C, Tosato G: A role for the interferon
inducible protein 10 in inhibition of angiogenesis by inter-
leukin-12. Ann.  NY Acad Sci 1996, 795:158-167.
13. van Moorsel CJ, Pinedo HM, Veerman G, Vermorken JB, Postmus PE,
Peters GJ: Scheduling of gemcitabine and cisplatin in Lewis
lung tumor bearing mice.  Eur J Cancer 1999, 35:808-814.
14. Lorusso V, Carpagnano F, Frasci G, Panza N, Di Rienzo G, Cisternino
ML, Napoli G, Orlando S, Cinieri S, Brunetti C, Palazzo S, De Lena M:
Phase I/II study of gemcitabine plus vinorelbine as first-line
chemotherapy of non-small-cell lung cancer.  J Clin Oncol 2000,
18:405-411.
15. Mei K, Tian L, Wei YQ, Li J, Wen YJ, Kan B, Deng HX: Antitumor
effects of interferon-gamma-inducible protein 10 combined
with gemcitabine.  Ai Zheng 2005, 24:397-402.
16. Wei YQ, Huang MJ, Yang L, Zhao X, Tian L, Lu Y, Shu JM, Lu CJ:
Immunogene therapy of tumors with vaccine based on
Xenopus homologous vascular endothelial growth factor as
a model antigen.  Proc Natl Acad Sci USA 2001, 98:11545-11550.
17. Wei YQ, Wang QR, Zhao X, Yang L, Tian L, Lu Y, Kang B, Lu CJ:
Immunotherapy of tumors with xenogeneic endothelial cells
as a vaccine.  Nat Med 2000, 6:1160-1166.
18. Liu JY, Wei YQ, Yang L, Zhao X, Tian L, Hou JM, Niu T, Liu F: Immu-
notherapy of tumors with vaccine based on quail homolo-
gous vascular endothelial growth factor receptor-2.  Blood
2003, 102:1815-1823.
19. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Over-
holser J, Hooper A, Pytowski B, Witte L, Bohlen P, Hicklin DJ: Anti-
vascular endothelial growth factor receptor (fetal liver
kinase 1) monoclonal antibody inhibits tumor angiogenesis
and growth of several mouse and human tumors.  Cancer Res
1999, 59:5209-5218.
20. Blezinger P, Wang J, Gondo M, Quezada A, Mehrens D, French M,
Singhal A, Sullivan S, Rolland A, Ralston R, Min W: Systemic inhibi-
tion of tumor growth and tumor metastases by intramuscu-
lar administration of the endostatin gene.  Nat Biotechnol 1999,
17:343-348.
21. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E,
Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous
inhibitor of angiogenesis and tumor growth.  Cell 1997,
88:277-285.
22. Arenberg DA, Kunkelfl SL, Polverini PJ, Morris SB, Burdick MD, Glass
MC, Taub DT, Iannettoni MD, Whyte RI, Strieter RM: Interferon-γ-
inducible protein 10 (IP-10) is an angiostatic factor that
inhibits human non-small cell lung cancer (NSCLC) tumori-
genesis and spontaneous metastases.  J Exp Med 1996,
184:981-992.
23. Wei YQ, Hang ZB, Liu KF: In situ observation of inflammatory
cell-tumor cell interaction in human seminomas (germino-
mas): light, electron microscopic, and immunohistochemical
study.  Hum Pathol 1992, 23:421-428.
24. Keyser J, Schultz J, Ladell K, Elzaouk L, Heinzerling L, Pavlovic J, Moe-
lling K: IP-10-encoding plasmid DNA therapy exhibits anti-
tumor and anti-metastatic efficiency.  Exp Dermatol 2004,
13:380-390.
25. Vanguri P, Farber JM: Identification of CRG-2: an interferon
inducible mRNA predicted to encode a murine monokine.  J
Biol Chem 1990, 265:15049-15057.
26. Bocci G, Danesi R, Marangoni G, Fioravanti A, Boggi U, Esposito I,
Fasciani A, Boschi E, Campani D, Bevilacqua G, Mosca F, Del Tacca M:
Antiangiogenic versus cytotoxic therapeutic approaches to
human pancreas cancer: an experimental study with a vascu-
lar endothelial growth factor receptor-2 tyrosine kinase
inhibitor and gemcitabine.  Eur J Pharmacol 2004, 498:9-18.
27. Storniolo AM, Allerheiligen SR, Pearce HL: Preclinical, pharmaco-
logic, and Phase I studies of gemcitabine.  Semin Oncol 1997,
24:S7-2.
28. Plate KH, Breier G, Weich HA, Risau W: Vascular endothelial
growth factor is a potential tumour angiogenesis factor in
human gliomas in vivo.  Nature 1992, 359:845-848.
29. Nor JE, Christensen J, Mooney DJ, Polverini PJ: Vascular endothe-
lial growth factor (VEGF)-mediated angiogenesis is associ-
ated with enhanced endothelial cell survival and induction of
Bcl-2 expression.  Am J Pathol 1999, 154:375-384.
30. Pertl U, Luster AD, Varki NM, Homann D, Gaedicke G, Reisfeld RA,
Lode HN: IFN-gamma-inducible protein-10 is essential for the
generation of a protective tumor-specific CD8 T cell
response induced by single-chain IL-12 gene therapy.  J Immu-
nol 2001, 166:6944-6951.
31. Taub DD, Longo DL, Murphy WJ: Human interferon-inducible
protein-10 induces mononuclear cell infiltration in mice and
promotes the migration of human T lymphocytes into the
peripheral tissues and human peripheral blood lymphocytes-
SCID mice.  Blood 1996, 87:1423-1431.
32. Nowak AK, Robinson BW, Lake RA: Gemcitabine exerts a selec-
tive effect on the humoral immune response: implications
for combination chemo-immunotherapy.  Cancer Res 2002,
62:2353-2358.